DVAX

[Terliso]

DVAX seems going into the hole;)

It's getting there.

.... about DVAX i'm concern about the RSI in the weekly chart it's so narrow as you can see it's now pointing down, I think DVAX will go down & possibly fill the gap... IMHO

I might be wrong but this is what I observed in a lot of stocks


goodluck!!

[REALDEALS21]

Good bounce off $6 support + some NEWS !!!!!!!


Press Release   Source: Dynavax Technologies Corporation

Dynavax's Universal Flu Vaccine Improves Response of Standard Flu Vaccines
Thursday October 19, 4:00 pm ET
Preclinical Studies Show TLR9 Agonists Conjugated to Conserved Viral Proteins Provide 30-Fold Dose-Sparing of Standard Vaccine Components

BERKELEY, Calif., Oct. 19 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX - News) today announced that tomorrow, Friday, October 20, at the Second International Conference on Influenza Vaccines for the World in Vienna, Austria, it is presenting new preclinical data that show its influenza (flu) vaccine can improve the immunogenicity of standard flu vaccines. Dynavax said that the data from mouse and primate models demonstrate that co-administration of Dynavax's flu vaccine with standard vaccine enhances the immune response of the standard vaccine, allows reduction of standard vaccine dosage, and provides extra layers of protection that are not strain-dependent. Dynavax's vaccine is based on the company's proprietary TLR9 agonist-based immunostimulatory sequence (ISS) technology. The work was funded in part by a $3.0 million research and development grant for a pandemic influenza vaccine from the National Institute of Allergy and Infectious Disease (NIAID), a division of the National Institutes of Health.

ADVERTISEMENT
Implications for Future Flu Vaccine Development

"Our findings in flu give us confidence about our ability to move forward quickly with a commercial product. In Dynavax's other infectious disease vaccine programs, preclinical data accurately predicted the results of subsequent human clinical trials," said Gary Van Nest, Ph.D., vice president of preclinical research at Dynavax.

Van Nest explained, "Standard flu vaccines provide protection against viral infection by generating neutralizing antibodies against viral surface proteins (hemagglutinin, or HA and neuraminidase, or NA). When there is inadequate antibody production or a mis-match between the vaccine and circulating virus, the effectiveness of standard vaccines can be dramatically reduced. The Dynavax universal flu vaccine not only enhances the virus-blocking, or neutralizing, effects of the co-administered standard flu vaccine, but also kills virus-infected cells and prevents virus spread that can lead to pneumonia and other often fatal sequellae, in a manner that is not strain-dependent."

"Our exciting results," added Van Nest, "are produced by linking our TLR9 agonists (ISS) to the highly conserved viral proteins, nucleoprotein (NP) and the extracellular domain of matrix protein 2 (M2e). NP-ISS induces strong type-1 helper T cell (Th1) and cytotoxic T cell responses (CTL) that kill virus-infected cells. M2e-ISS induces strong cytotoxic antibody responses that also kill infected cells, limiting disease severity. In effect, even if a standard flu vaccine does not match the virus that circulates in the season, our universal flu vaccine can potentially protect against viral disease, when combined or co-administered with any standard flu vaccine."

Data from Vienna

In the presentation in Vienna, entitled, "Induction of Broadly Protective Cellular Immune Responses Using an ISS Conjugate Vaccine," Debbie Higgins, Dynavax Senior Manager, Preclinical Programs, describes the work of Dynavax and its collaborators at The Influenza Research Center, Baylor College of Medicine.

The studies suggest that by adding the ISS-linked conserved antigens to standard vaccines, it may be possible to increase the effectiveness of any standard trivalent influenza vaccine or allow dose-reduction of standard vaccines and at the same time, increase their effectiveness. The data show the enhancement of functional antibody responses against the vaccine strains, specifically:

    -- In mice, NP-ISS co-administered with standard vaccine (Fluzone®,
       sanofi-aventis) provided significantly higher antibody responses with
       30-fold less Fluzone.

    -- Primates (baboons) immunized with NP-ISS co-administered with standard
       vaccine developed enhanced Fluzone-specific antibody responses as
       measured by hemagglutination inhibition and viral neutralization
       assays.

    -- Linking ISS to a short M2e peptide (M2e-ISS) generated a strong
       M2e-specific antibody response.

In August 2006, at the "Novel Vaccines: Bridging Research, Development and Production" conference in Cambridge, MA, Dynavax presented data that showed both its flu vaccine's ability to confer cross-protective cellular immunity against widely divergent flu strains in mice and its potential as a universal flu vaccine. The data suggest that the vaccine has the potential to eliminate annual vaccinations and enable the stockpiling of vaccine for pandemic use. Specifically, the Dynavax flu vaccine was shown to protect against both "antigenic drift" and "antigenic shift." Mice immunized with the NP-ISS conjugate and then challenged with drift and shift virus strains demonstrated statistically significant lower viral titers and higher survival rates compared to mice immunized with NP alone or a PBS placebo.


P
Dynavax to Show Positive Flu Drug Data
Thursday October 19, 6:10 pm ET
Dynavax Technologies to Present Positive Preclinical Data on Flu Vaccine

BERKELEY, Calif. (AP) -- Drug developer Dynavax Technologies said it will present preclinical data Friday showing its flu vaccine candidate can improve the effectiveness of other flu vaccines.

The data will be presented at the Second International Conference on Influenza Vaccines for the World, in Vienna. The data from a study on involving mice and primate models showed its flu vaccine, when given with other standard vaccines, increases the immunogenicity, or the immune response, of the standard vaccines. That means it would allow for the reduction of dosages in standard vaccine and provide extra layers of protection that aren't strain-dependent.

ADVERTISEMENT
The study was funded in part with $3 million from the National Institutes of Health as part of a grant to develop a pandemic flu vaccine. Dynavax is developing its vaccine based on a TLR9 agonist.

Shares of Dynavax fell 42 cents, or 6.4 percent, to close at $6.13 on the Nasdaq, but rebounded 37 cents, or 6 percent, to $6.50 in aftermarket activity.

[stocks2watch2]

DVAX is on the move again,bought @ 7.65
Dynavax upped to outperform at Bear Stearns 

[stocks2watch2]

Bought more averaged down to 7.52,

UPDATE 1-RESEARCH ALERT-Bear Stearns upgrades Dynavax
Reuters - November 17, 2006 10:41 AM ET
   
Related Quotes
Symbol   Last Chg
DVAX Trade 7.58 +1.00
Real time quote.
 
(Changes source, recasts, adds details)

Nov 17 (Reuters) -

DYNAVAX TECHNOLOGIES CORP. (DVAX)

Current Prior Rating Outperform Peer Perform

--Bear Stearns said it upgraded the drug maker on expectations of positive data from its ragweed allergy vaccine, Tolamba, in early-2007, among other reasons.

--The brokerage said it expects a partnership for Tolamba if the phase 3 data are positive in early-2007 and views a deal with a global pharma partner as a major catalyst for the stock.

--The brokerage has a year-end 2007 price target of $10 on the stock, which rose more than 15 percent to $7.57 in morning trade on the Nasdaq. (Reporting by Tenzin Pema in Bangalore)

[stocks2watch2]

Breaking out to the HOD @ 7.94

[stocks2watch2]

Sold 1/2 @ 8.08

[kslifka]

Smoking after hours

http://biz.yahoo.com/prnews/061128/sftu131.html?.v=50

[setravis]

DYNAVAX TECHNOLOGIES (NasdaqGM:DVAX) Delayed quote data 

Last Trade: 10.02
Trade Time: 9:34AM ET
Change:  2.62 (35.41%)
Prev Close: 7.40
Open: 9.43
Bid: 9.97 x 300
Ask: 9.98 x 200
1y Target Est: 9.00

  Day's Range: 9.21 - 9.94
52wk Range: 3.62 - 8.20
Volume: 3,096,524
Avg Vol (3m): 1,449,920
Market Cap: 380.15M
P/E (ttm): N/A
EPS (ttm): -1.47
Div & Yield: N/A (N/A)

[kslifka]

Got stopped out of DVAX at 9.90...but it's looking good into the close.  No black candle for this one.

[kslifka]

I don't own DVAX(no funds).  But it's looking like it could be ready to make another move

[setravis]

When they get these small stocks going in the correct direction,
the selling stops and hence...profits seems simple enough
to bad I can't do it better.
3SOF is a great place to build good trading habits and skills, hopefully to use with the real moo-la...


52wk Range: 1.51 - 6.55
Volume: 717,350
Avg Vol (3m): 318,008

Technicals
Percentage Gainer

Last Price Quote is:
31.72%above 13-day MA
-11.84%below 50-day MA
RS Rating: 3 

Fundamentals
Earnings Expected on May 7

Key Data:
Market Cap (M): $62.09 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 08/05/2008
Last Analyst Rating: Mkt Perform

[setravis]

updated chart look.......

[setravis]

A 'Pandemic' Now Declared, Focus Back on Swine Flu Stocks
On Friday June 12, 2009, 12:00 pm EDT

The H1N1 virus is officially a pandemic, and vaccine stocks are responding.

Swine flu stocks are up again today, with some extending weekly gains to more than 20%. A number of companies released good news to end the week. From small-cap players to multi-billion dollar giants, shares are up big on high volume. Novartis (NYSE: NVS) announced today that it will have a swine flu vaccine ready by this fall. Shares are up by 4% on the news.

On Thursday, the World Health Organization raised its alert level on the virus to "Phase 6," indicating that it has officially become a pandemic.

As a whole the Swine Flu and Bird Flu Stocks Index is up by 2.5%. It is now beating the S&P 500 by 35.5% over the last month.

Generex Biotechnology (NASDAQ: GNBT) is leading the Index today with 10% gains. The company was granted five new patents for its drug delivery systems. The patents were awarded in Canada, Australia, New Zealand, Brazil, and Lebanon. The stock is still in negative territory this week by -3%.

Sinovac Biotech (AMEX: SVA) is adding another 3% to its industry-leading 30% weekly rally. On Monday the company announced that it had begun production of a swine flu vaccine, and noted that it could produce up to 30 million doses per year.

Vical (NASDAQ: VICL) has fallen from earlier highs, and is now trading up fractionally. Thomas Weisel initiated coverage of the company today with an Overweight rating and a $5 price target. The analyst cited Vical's proprietary technology, strategic partnerships, and licensing agreements.

GlaxoSmithKline (NYSE: GSK) and Hemispherx Biopharma (AMEX: HEB) are both ahead by more than 4% today.

Pure Bioscience (NASDAQ: PURE) and AVI Biopharma (NASDAQ: AVII) are industry laggards today, falling by -3% and -6% respectively.

As of this writing the Swine Flu and Bird Flu Stocks Index is a top-three performing tickerspy Index over the last month, gaining 39.5%.

Investors can follow the Swine Flu and Bird Flu Stocks Index and view related performance charts and metrics at tickerspy.com.

Investors can follow the Swine Flu and Bird Flu Stocks Index and view related performance charts and metrics at tickerspy.com.
http://www.tickerspy.com/index/Swine-Flu-and-Bird-Flu-Stocks?refer=2028Y3